Targeting GSK-3 family members in the heart: A very sharp double-edged sword

Hui Cheng, James Woodgett, Mia Maamari, Thomas Force

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

The GSK-3 family of serine/threonine kinases, which is comprised of two isoforms (α and β), was initially identified as a negative regulator of glycogen synthase, the rate limiting enzyme of glycogen synthesis [1,2]. In the 30. years since its initial discovery, the family has been reported to regulate a host of additional cellular processes and, consequently, disease states such as bipolar disorders, diabetes, inflammatory diseases, cancer, and neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease [3,4]. As a result, there has been intense interest on the part of the pharmaceutical industry in developing small molecule antagonists of GSK-3. Herein, we will review the roles played by GSK-3s in the heart, focusing primarily on recent studies that have employed global and tissue-specific gene deletion. We will highlight roles in various pathologic processes, including pressure overload and ischemic injury, focusing on some striking isoform-specific effects of the family. Due to space limitations and/or the relatively limited data in gene-targeted mice, we will not be addressing the family's roles in ischemic pre-conditioning or its many interactions with various pro- and anti-apoptotic factors. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

Original languageEnglish (US)
Pages (from-to)607-613
Number of pages7
JournalJournal of Molecular and Cellular Cardiology
Volume51
Issue number4
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Glycogen Synthase Kinase 3
Protein Isoforms
Glycogen Synthase
Ischemic Preconditioning
Protein-Serine-Threonine Kinases
Gene Deletion
Drug Industry
Pathologic Processes
Glycogen
Bipolar Disorder
Neurodegenerative Diseases
Hypertrophy
Alzheimer Disease
Heart Failure
Pressure
Wounds and Injuries
Enzymes
Genes
Neoplasms

Keywords

  • Cardiac hypertrophy
  • Glycogen synthase kinase 3
  • Metabolism
  • Therapeutic potential

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Targeting GSK-3 family members in the heart : A very sharp double-edged sword. / Cheng, Hui; Woodgett, James; Maamari, Mia; Force, Thomas.

In: Journal of Molecular and Cellular Cardiology, Vol. 51, No. 4, 01.10.2011, p. 607-613.

Research output: Contribution to journalReview article

Cheng, Hui ; Woodgett, James ; Maamari, Mia ; Force, Thomas. / Targeting GSK-3 family members in the heart : A very sharp double-edged sword. In: Journal of Molecular and Cellular Cardiology. 2011 ; Vol. 51, No. 4. pp. 607-613.
@article{18da72b5f1634d189dd222a6165bd8f4,
title = "Targeting GSK-3 family members in the heart: A very sharp double-edged sword",
abstract = "The GSK-3 family of serine/threonine kinases, which is comprised of two isoforms (α and β), was initially identified as a negative regulator of glycogen synthase, the rate limiting enzyme of glycogen synthesis [1,2]. In the 30. years since its initial discovery, the family has been reported to regulate a host of additional cellular processes and, consequently, disease states such as bipolar disorders, diabetes, inflammatory diseases, cancer, and neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease [3,4]. As a result, there has been intense interest on the part of the pharmaceutical industry in developing small molecule antagonists of GSK-3. Herein, we will review the roles played by GSK-3s in the heart, focusing primarily on recent studies that have employed global and tissue-specific gene deletion. We will highlight roles in various pathologic processes, including pressure overload and ischemic injury, focusing on some striking isoform-specific effects of the family. Due to space limitations and/or the relatively limited data in gene-targeted mice, we will not be addressing the family's roles in ischemic pre-conditioning or its many interactions with various pro- and anti-apoptotic factors. This article is part of a special issue entitled {"}Key Signaling Molecules in Hypertrophy and Heart Failure{"}.",
keywords = "Cardiac hypertrophy, Glycogen synthase kinase 3, Metabolism, Therapeutic potential",
author = "Hui Cheng and James Woodgett and Mia Maamari and Thomas Force",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.yjmcc.2010.11.020",
language = "English (US)",
volume = "51",
pages = "607--613",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting GSK-3 family members in the heart

T2 - A very sharp double-edged sword

AU - Cheng, Hui

AU - Woodgett, James

AU - Maamari, Mia

AU - Force, Thomas

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The GSK-3 family of serine/threonine kinases, which is comprised of two isoforms (α and β), was initially identified as a negative regulator of glycogen synthase, the rate limiting enzyme of glycogen synthesis [1,2]. In the 30. years since its initial discovery, the family has been reported to regulate a host of additional cellular processes and, consequently, disease states such as bipolar disorders, diabetes, inflammatory diseases, cancer, and neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease [3,4]. As a result, there has been intense interest on the part of the pharmaceutical industry in developing small molecule antagonists of GSK-3. Herein, we will review the roles played by GSK-3s in the heart, focusing primarily on recent studies that have employed global and tissue-specific gene deletion. We will highlight roles in various pathologic processes, including pressure overload and ischemic injury, focusing on some striking isoform-specific effects of the family. Due to space limitations and/or the relatively limited data in gene-targeted mice, we will not be addressing the family's roles in ischemic pre-conditioning or its many interactions with various pro- and anti-apoptotic factors. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

AB - The GSK-3 family of serine/threonine kinases, which is comprised of two isoforms (α and β), was initially identified as a negative regulator of glycogen synthase, the rate limiting enzyme of glycogen synthesis [1,2]. In the 30. years since its initial discovery, the family has been reported to regulate a host of additional cellular processes and, consequently, disease states such as bipolar disorders, diabetes, inflammatory diseases, cancer, and neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease [3,4]. As a result, there has been intense interest on the part of the pharmaceutical industry in developing small molecule antagonists of GSK-3. Herein, we will review the roles played by GSK-3s in the heart, focusing primarily on recent studies that have employed global and tissue-specific gene deletion. We will highlight roles in various pathologic processes, including pressure overload and ischemic injury, focusing on some striking isoform-specific effects of the family. Due to space limitations and/or the relatively limited data in gene-targeted mice, we will not be addressing the family's roles in ischemic pre-conditioning or its many interactions with various pro- and anti-apoptotic factors. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

KW - Cardiac hypertrophy

KW - Glycogen synthase kinase 3

KW - Metabolism

KW - Therapeutic potential

UR - http://www.scopus.com/inward/record.url?scp=80052816865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052816865&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2010.11.020

DO - 10.1016/j.yjmcc.2010.11.020

M3 - Review article

C2 - 21163265

AN - SCOPUS:80052816865

VL - 51

SP - 607

EP - 613

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 4

ER -